Vascular smooth muscle contractile apparatus and associated signaling (VSMC contractile apparatus)

The vascular smooth muscle contractile apparatus and its associated signaling pathways constitute the fundamental mechanism for controlling vascular resistance and systemic blood pressure (Webb, 2003, Adv Physiol Educ). At its core, contraction is triggered by the phosphorylation of the 20-kDa myosin light chain (MLC20) by myosin light chain kinase (MLCK), which is activated by the calcium-calmodulin complex (Somlyo & Somlyo, 2003, Physiol Rev). Conversely, relaxation is mediated by myosin light chain phosphatase (MLCP), which dephosphorylates MLC20 (Grassie et al., 2011, Biochem J). This system is further regulated by calcium sensitization pathways, most notably the RhoA/Rho-kinase (ROCK) pathway, which inhibits MLCP, and the nitric oxide (NO)/cGMP pathway, which promotes MLCP activity (Shimokawa & Satoh, 2015, Expert Rev Cardiovasc Ther). Dysfunction in these signaling cascades is a hallmark of various cardiovascular pathologies, including hypertension, pulmonary arterial hypertension, and vasospastic disorders (Sanders, 2008, Neurogastroenterol Motil). Therapeutic agents like calcium channel blockers, nitrates, and ROCK inhibitors target different nodes within this apparatus to modulate vascular tone and improve hemodynamics.

Other names

Vascular smooth muscle contraction pathwayVSMC signalingMyosin-actin contractile machineryVascular smooth muscle excitation-contraction coupling

Drugs targeting this system work by either reducing intracellular calcium concentrations, inhibiting kinases like Myosin Light Chain Kinase (MLCK) or Rho-associated protein kinase (ROCK), or enhancing the activity of Myosin Light Chain Phosphatase (MLCP) via the NO/cGMP pathway, all of which lead to decreased myosin light chain phosphorylation and subsequent vasodilation.